Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapid Micro BiosystemsRPID +0.59%60 Cash Ratio is 1.09 as of Jun. 2026, which is 78% below its 10-year median of 4.98. GuruFocus rates RPID with a GF Score™ of 60/100 and a GF Value™ of $1.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Rapid Micro Biosystems ranks better than 53.03% on this metric.
Rapid Micro Biosystems has a Cash Ratio of 1.09. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Rapid Micro Biosystems's Cash Ratio or its related term are showing as below:
RPID'
s Cash Ratio Range Over the Past 10 Years
Min: 1.09 Med: 4.98 Max: 12.39
Current: 1.09
During the past 7 years, Rapid Micro Biosystems's highest Cash Ratio was 12.39. The lowest was 1.09. And the median was 4.98.
RPID's Cash Ratio is ranked better than 53.03% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs RPID: 1.09
Rapid Micro Biosystems (NAS:RPID) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Rapid Micro Biosystems's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Micro Biosystems Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Micro Biosystems (RPID) has a Cash Ratio of 1.09 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rapid Micro Biosystems and its competitors. This is 78% below median its historical median of 4.98. Over the past decade, Rapid Micro Biosystems' Cash Ratio has ranged from 1.09 to 12.39. According to the industry distribution chart, Rapid Micro Biosystems ranks #395 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is Rapid Micro Biosystems' Cash Ratio too high?
Rapid Micro Biosystems' current Cash Ratio of 1.09 is 78% below median its 10-year median of 4.98. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 12.39. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Rapid Micro Biosystems' value of 1.09 is 11.2% above this industry median. Based on the distribution chart, Rapid Micro Biosystems ranks #395 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Rapid Micro Biosystems has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Cash Ratio compare to HYPR and ZOMDF?
According to the Medical Devices & Instruments industry distribution chart, Rapid Micro Biosystems ranks #395 out of 841 companies for Cash Ratio. This puts Rapid Micro Biosystems in the upper half of its industry. The industry median Cash Ratio is 0.98. Rapid Micro Biosystems' value of 1.09 is 11.2% above this benchmark. Historically, Rapid Micro Biosystems' own Cash Ratio has ranged from 1.09 to 12.39 over the past decade. While the company's 10-year median is 4.98 vs. the industry median of 0.98, Rapid Micro Biosystems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Micro Biosystems's current Cash Ratio of 1.09 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rapid Micro Biosystems and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Micro Biosystems's current Cash Ratio is 1.09, which is 78% below median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.89, compared to a current price of $1.70 — trading 10.1% below its estimated fair value. The current Cash Ratio is 1.09, which is 78% below median its 10-year median of 4.98 and 11.2% above the Medical Devices & Instruments industry median of 0.98. Rapid Micro Biosystems' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Cash Ratio is 1.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be undervalued.
The current stock price of $1.70 is trading 10.1% below its estimated GF Value™ of $1.89.
GuruFocus considers Rapid Micro Biosystems to be Modestly Undervalued.
Key valuation signals for RPID:
Cash Ratio: 1.09 (78% below median its 10-year median of 4.98)
GF Value™: $1.89 vs. price of $1.70 (10.1% below fair value)
Industry Position: 11.2% above the Medical Devices & Instruments median (#395 of 841)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
60GF Score
Get the complete analysis for RPID
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
